Completed Clinical Trials

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

By April 24, 2017 No Comments


Mesothelioma|Lung Cancer

Estimated Enrollment: 662

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment

Study ID Numbers: 0683-014|2005_010|CTRI/2009/091/000146

Study First Received: August 5, 2005

Last Updated: April 17, 2015

Estimated Primary Completion Date: July 2011


Primary Outcome Measures:

Overall survival|Number of participants with adverse events characterized as Grade 3/4 according to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE)|Progression-free survival|Objective response rate|Percent change from baseline in dyspnea score of the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)|Percent change from baseline in forced vital capacity (FVC)

Sponsors and Collaborators:

Merck Sharp & Dohme Corp.

Website Link:

Leave a Reply

Call Now ButtonCall Now